Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Planning To Ban Gene Editing Technology Exports

Hindrance To Growing Sector?

Executive Summary

Beijing’s latest proposal to ban gene editing is viewed as a direct response to Washington’s tightening grip over the transfer of US technology to China.

You may also be interested in...

Chinese Language Podcast: 集采, ADC交易, 基因编辑出口和中国生物制药内在矛盾

Recent major ADC deals, volume-based procurement (Jicai), China’s plan to ban gene-editing technology exports and the biotech paradox in China are the main topics for this new China Biotech Hot Topic podcast. Brian Yang and Dexter Yan discuss key aspects to watch and the implications for major players as well as the wider pharma sector.

China's Gene-Editing Baby Scientist Stirs Up Rare Disease Controversy

Jiankui He, the researcher behind China's world-shocking gene-edited babies scandal, now leaps into rare diseases research area but ethics oversight remain murky.

Chinese Biopharma Tycoons Down But Not Out In Latest Global Billionaire Ranking

China continues to dominate the latest list of global billionaires and top execs from domestic pharma firms Hengrui and Hansoh ranked among the wealthiest overall in the country, along with the founder of vaccine maker Zhifei Bio. A number of top Chinese biopharma business executives also featured in the global top 100 billionaires list.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts